Prudential plc (PRU) Earnings Call Transcript
August 27, 2026
Earnings Call Speaker Segments
Good day, everyone. Anil Wadhwani here, Prudential's chief executive. Appreciate you joining us. I'm pleased to take you through the results for the first half of 2026 and update you on where we stand in executing our strategy. What I want you to take away today is simple. Prudential remains focused on the plan we set out — generating high-quality growth, producing robust capital and cash, and positioning the group for long-term success across the growth markets of Asia and Africa. We continue to execute with discipline, harnessing the benefits of Prudential's diversified growth engines — spanning multiple markets and channels — for all our stakeholders. Our first half is a reflection of that. We saw expansion across the board, with margins widening, underlying variances turning favorable, and earnings, capital, and cash generation remaining robust. What matters here is that this growth is high quality. The business we're writing produces appealing margins, converts strongly into cash, and generates capital in a resilient way. Through that, we're building lasting value for every stakeholder. Our emphasis on long-term savings and protection is also well aligned with what the regulator wants for the insurance sector. Meanwhile, we're deploying capital prudently—putting money into long-term growth in Malaysia and India, for instance, even as we keep raising what we return to shareholders. Accordingly, we plan to add $0.3 billion on top of the $1.2 billion 2026 share buyback program we announced earlier; we're bolstering how we compete in markets that are growing structurally throughout Asia and Africa. Through what we invest in distribution, propositions and technology, Prudential is positioned to seize that opportunity as time goes on, which creates a substantial and lasting runway for growth. To sum up, executing with discipline is producing quality growth, stronger capital generation and more shareholder value, all while putting Prudential in place for continued long-term growth. New business profit for the first half of 2026 came to $1.4 billion, an increase of 8%, or 10% if you exclude the Chinese Mainland. Adjusted operating profit after tax rose 17% per share. Gross operating free surplus generation rose 15%, reaching $1.8 billion, while dividend per share was up 15% as well. Our capital generation is still robust, and it backed $1 billion in shareholder returns during the first half via dividends and the share buyback program. Our attention stays squarely on delivering our full year 2026 guidance — double-digit growth in new business profit, gross OFSG and adjusted EPS, along with double-digit dividend per share growth — and on hitting our 2027 financial objectives. We are moving quickly on execution across agency, bancassurance, health and customer. On agency transformation, we're seeing steady progress — new business profit is up 5%, compared with 4% for the full year of 2025. We know there's more work ahead, and we're continuing to roll out our plans to lift performance in this key distribution channel. Bancassurance had another excellent quarter, with new business profit rising 13%, helped by deeper strategic partnerships and a wider partner base. Outside the Chinese Mainland, bancassurance was up 18%. Health new business profit rose 15% as we keep building on our health strengths to extend further into protection. And we're reshaping and reimagining the customer experience through better technology, operations, and AI. This is producing better outcomes, and engagement now scales in a more effective way. Take our Customer Engagement Platform as an example — it's live in 10 markets today and has helped drive more than $330 million in sales across the first half, while our retention rate sits at a solid 94%. Underpinning those numbers is a $1 billion strategic investment program aimed at building capabilities and modernizing our infrastructure. Roughly $700 million has gone in since 2023, with $145 million of that in the first half of this year, as we continue developing distribution and customer capabilities and meaningfully upgrade our technology platform. Our growth stays high quality, broad-based, and balanced across channels and markets. Choosing quality growth is intentional. Our emphasis is on generating business that delivers appealing margins, solid profitability, persistence, and improved cash conversion. That is reflected in expanding margins, robust aggregate IRRs exceeding 25%, and quick payback periods; contributions were broad-based across our multi-market growth engine model. Greater China's new business profit increased 5%, while ASEAN markets saw a 13% rise. In India, APE sales grew 11%, and in Africa they were up 19%. Eastspring, our asset manager, achieved 20% operating profit growth on a like-for-like basis, and funds under management grew 5% to $291 billion. Our distribution mix stays well balanced: agency accounted for 53% of first half new business profit, bancassurance 42%, and all other channels together, brokers included, 5%. That balance is important since it provides us with resilience and flexibility. Higher-quality advice and deeper customer engagement are supported by our proprietary channels, while we serve customers through whichever channels best suit their needs. Now turning to the Chinese Mainland. Entering 2026, we carried strong momentum. In the first quarter, APE rose 42%, with very strong momentum in both agency and bancassurance. In the second quarter, however, bancassurance declined following the implementation of more prescriptive expense regulations. For the first half overall, APE was up 21%. New business profit fell 4%, reflecting an accelerated shift toward participating products. The par mix rose from 35% to 76% of APE, which compressed new business profit margins. On top of that, we're coordinating closely with our bancassurance partners while the channel adjusts to the new expense rules. We view these regulatory shifts as helping build a healthier and more sustainable industry in the long run, though they do bring some near-term transition effects. Our strategic tie with CITIC Bank keeps getting stronger, and we grew our preferred bank network from 50 branches to over 80. Meanwhile, agency transformation keeps moving forward, with APE per active agent rising 24% and MDRT qualifiers climbing 40%. In the third quarter, the Chinese Mainland is up against a tough bancassurance comparison, which becomes substantially easier starting in September. For the full year, we expect new business profit to fall within a range similar to 2025's. We remain focused on transforming the agency channel, restoring momentum in bancassurance, and rebalancing the product mix, while keeping quality and capital efficiency squarely in view. We have successfully navigated through earlier periods of change. While that creates some near-term transition effects, it does not lessen the medium- to long-term potential, and we continue to see considerable long-term growth opportunity in the Chinese Mainland market. The composition of our Hong Kong business appeals to me greatly. It is now more balanced between domestic and Chinese Mainland visitors, and across agency and bancassurance. Our emphasis on generating quality growth delivered a 7 percentage point improvement in margins overall across both our proprietary channels of agency and bancassurance. All in all, new business profit was up 8%. Bancassurance, for its part, rose 48% as it took in wealth flows, while agency advanced 4% versus a tough comparator. Our domestic customer segment—which these days accounts for roughly half of new business profit—put in a strong showing, helped along by demand from new residents, with new business profit up 22%. CMV new business profit slipped 2% against an exceptionally strong prior-year comparator. We stay very upbeat about our Hong Kong business, in light of how strong our multichannel model is, the balance between domestic and CMV, and our focus on longer-pay savings, health and protection, and regular premium products.
That's the reason we keep aiming for double-digit growth in Hong Kong across the full year, and the high comparator base from July and August will begin to soften starting in September. As for the recent talk about tightening the existing rules for Chinese Mainland customers, in our view it's too soon to say how this could affect customer behavior. From our discussions with customers and agents, the fundamental demand drivers for insurance in Hong Kong are still very strong. Retention rates continue to be very high, roughly 99% in both the domestic and CMV segments. This shows the ongoing appeal of our propositions and is backed by our latest customer survey, which strengthens our confidence in the structural growth prospects of our Hong Kong business. ASEAN keeps performing well, with momentum building across the region, driven by our underlying transformation. All in all, new business profit rose 13% in the first half and new business profit margins gained 2 percentage points; in Singapore, we achieved double-digit volume growth in both the first and second quarters. We refreshed and widened our health and protection offerings, adding new critical illness solutions. We recorded 39% growth in investment-linked products, reflecting sustained demand for wealth and savings solutions. Agency productivity rose, with new business profit per active agent increasing 9% and average case size climbing 23%; in Malaysia, new business profit increased 46%, helped by propositions that assist customers in upgrading their health cover so it better matches their current needs. This was complemented by more specialized advice for affluent and high-net-worth customers, with new business profit per active agent rising 29% and agency new business profit up 36%. In Indonesia, the first half proved challenging because of the macro environment, including inflationary pressure, volatile equity markets and a depreciating currency, which weighed on customer sentiment. Bancassurance did very well, rising 55%, supported by demand for U.S. dollar products and a higher mix of affluent customers, while agency was affected by a strong prior year comparator and weaker customer sentiment. In Thailand, product innovation and partnership execution drove strong growth. Our investment-linked offering, aimed at affluent and upper-affluent customers, together with our partnership with TMBThanachart Bank, known as ttb, contributed to 41% APE growth in the first half. The theme holds steady: growing our proprietary multichannel distribution model, while enhancing the quality and productivity of our agents, and using product innovation to engage emerging affluent and affluent customers across the attractive markets of ASEAN. India ranks among Asia's significant long-term growth opportunities. Our strategy is to take a more active role and shape our growth trajectory through 2 complementary insurance platforms: life and health. In life, our proposed acquisition of a 75% controlling stake in Bharti Life, subject to regulatory approval, would fundamentally reposition our platform. It shifts us from passive minority participation to an active operating platform in a market with significant long-term potential; we are excited to be partnering with Bharti Airtel and 360 ONE. Combining Bharti Airtel's omnichannel footprint with 360 ONE's relationships among affluent, high-net-worth and institutional clients gives us a better path to broaden distribution, extend customer access and bring Prudential's capabilities to bear more directly. On health, we committed to launching our stand-alone business in the second half; that launch has now happened, and I'm pleased that we issued our first policies earlier this month. Life and health combined provide the groundwork for a scalable franchise in India, in step with the country's long-term goal of Insurance for All by 2047. We are focused on constructing a high-quality business offering a differentiated customer experience and regional expertise, plus a strong position in health, where unmet demand is substantial; we are investing over the long term in a structurally attractive market, where our capabilities can be applied and sustainable value created. Eastspring remains a significant value creator and a key point of differentiation for Prudential. During the first half, operating profit after tax rose 20% on a like-for-like basis, and funds under management climbed 5% to $291 billion. Results benefited from $5.7 billion of positive net flows, diversified funding sources and strong investment performance, with 74% of funds beating their 3-year benchmarks. This business generates substantial cash, with a strong ROE and a disciplined cost-income ratio. Eastspring is well placed to capture rising wealth flows and growing retirement needs throughout Asia. Its scale, diversified funds under management, strong investment performance and deep local market expertise provide a clear platform for growth. From a strategic standpoint, it is an important differentiator for Prudential, reinforcing our life businesses via its investment capabilities and co-developed solutions while generating synergies between the 2 businesses. Agency stays central to our quality growth strategy, accounting for 53% of first half new business profit. In the first half, agency new business profit rose 5%, margin improved by 2 percentage points, and new business profit per active agent was up 9%. Crucially, productivity is rising in both developed and Emerging ASEAN; in developed markets, active agents held broadly stable and productivity rose 5%. In Emerging ASEAN, active agents declined, yet productivity rose 19%. That strengthens our conviction that the opportunity in agency isn't merely about scale. It concerns building a more professional, productive and active agency force. Agent quality matters since customer needs are growing more complex, particularly among affluent customers and in health and protection, which requires trusted high-quality advice; we remain the #2 MDRT agency force globally, and building that top-tier pipeline stays a key lever. The opportunity now is to keep raising productivity across both developed markets and Emerging ASEAN, while enhancing activation and quality recruitment where the need is greatest. When it comes to speeding up productivity and boosting the quality of recruitment, here's what I'd like to stress: we're sharply focused on raising the share of agents who make it into the top-producer group, especially MDRT agents; lifting productivity with AI and tech tools, including PRUAction; reinforcing what we offer customers in affluent high-net-worth, health and protection; overhauling how we recruit through efforts like PRUVenture, which back high-caliber entry-level hires; and running targeted training and upskilling for agents; agency transformation, we recognize, takes multiple years, yet our course is clear. We're creating an agency force of higher quality, greater professionalism and stronger productivity, with additional agents advancing along the productivity curve. Bancassurance turned in an outstanding result, generating 42% of first half new business profit. We're now set to hit the target range for our 2027 bancassurance goal during 2026, 12 months ahead of schedule. New business profit climbed 13%, and margins gained 1 percentage point. This outcome stems from the strength of our exclusive strategic partnerships. Such relationships open the door to target customer segments, quality distribution and a platform for scaling relevant propositions. We're taking these partnerships deeper via specialist models, stronger frontline execution and digital and AI-enabled tools. Simultaneously, we're extending our reach through nonexclusive partnerships and building a pipeline of new digital banking partners. For us, bancassurance is a key distribution channel, and it puts us in a strong position to capture the wealth flows moving across Asia.
One-Tech serves as the foundation of our digital investment program, taking us away from fragmented digital stacks toward a single, scalable platform spanning the entire group. Building on that base, our business-led approach is weaving AI into customer journeys, which helps customers get faster service, more relevant solutions and better support. Combined, our modernized technology platform and AI-enabled capabilities are enhancing customer experiences, boosting straight-through processing, cutting processing times and raising agent experience and productivity. The value this is already unlocking excites me. It shows up as faster, simpler digital servicing for customers via PRUServices, stronger digital lead generation for agents, higher sales through our Customer Engagement Platform, and greater productivity via PRUAction, our agent performance management tool. Our capital allocation approach stays disciplined. We keep investing in organic growth, strengthening the business and returning capital to our shareholders. This rests on a strong balance sheet position and predictable capital generation; we remain committed to giving back more than $7 billion of capital to shareholders between 2024 and 2027; and now for 2026, we expect to raise our existing buyback program by approximately $0.3 billion; that brings expected shareholder returns for the year to more than $2 billion through ordinary dividends and other capital returns. In the same way, we stay firmly focused on delivering our full year 2026 guidance of double-digit growth in new business profit, adjusted EPS, gross OFSG and dividend per share. Turning to the 2022–2027 target we set: new business profit growing at a compound annual rate of 15% to 20%, and gross OFSG exceeding $4.4 billion by 2027. Our confidence rests on long-term structural demand throughout the markets we serve. Demand for protection, health, savings and retirement solutions continues to be propelled by favorable demographics, rising wealth flows and low insurance penetration; and with a trusted brand, multichannel distribution, strong market positions and asset management capabilities, Prudential is well placed to capture these opportunities as time goes on, which gives us a substantial and enduring long-term growth runway. To finish, let me remind you of our journey. We're now nearly four years through a strategy that runs five years, and the progress has been substantial; the business has been reset and we've built stronger capabilities via our billion-dollar investment program — putting money into modernizing technology, operations, AI and data, with renewed emphasis on customer, distribution and health. Those investments are now producing better customer experiences, distribution that scales more readily and stronger execution across agency, bancassurance and health. Alongside that, we've reshaped the portfolio and allocated capital with discipline, acting in India, Malaysia, Eastspring and Africa to reinforce the group's long-term growth profile. We've also lifted returns to shareholders, backed by the strength of our capital generation and balance sheet. To wrap up: Prudential is acting with discipline—generating durable, premium growth, reinforcing its capital base for the long haul, and lifting value for shareholders. Our attention stays squarely on meeting the 2026 guidance and hitting the 2027 financial targets. I'll now pass things to our CFO, Ben Bulmer.
Thanks, Anil. Good morning, everyone — Ben Bulmer here, Prudential plc's CFO. I'm happy to say that in the first half of 2026, Prudential once again achieved strong, high-quality expansion alongside rising returns for shareholders. Double-digit increases came through in 3 of the 4 key financial KPIs we track from our operations. In aggregate, we posted growth as follows: new business profit, or NBP, rose 8%; operating profit per share climbed 17%; capital generation — gross OFSG — was up 15%; and the first interim dividend per share rose 15%, which, as always, is fixed at 1/3 of the full year dividend per share from the prior year; our attention stays fixed on active, disciplined capital allocation, consistent with the framework introduced last year; we keep putting money into quality organic new business as well as the capabilities needed to transform the group and underpin sustainable growth. Alongside that, we've made moves to reinforce our strategic portfolio. In India, we announced an agreement to take a 75% controlling stake in Bharti Life, shifting us from a passive to an active growth platform; we've also secured approval to launch our stand-alone health business. And in Malaysia, we lifted our holding in our conventional life insurance business to 70%. Beyond that, over the first half of 2026 we handed back more than $1 billion to shareholders via dividends and buybacks; we anticipate raising our 2026 buyback of $1.2 billion by circa $0.3 billion, with our current capital market actions providing the funding. Our earlier guidance on capital returns for 2027 is reconfirmed; we expect to return $1.3 billion on top of the ordinary dividend, which means over $7 billion of returns to shareholders across the 2024 to 2027 period. Our sights remain firmly set on delivering our 2026 guidance of double-digit growth across our 4 financial KPIs, and on hitting our 2027 financial objectives. As usual, I'll now take you through our results in more detail, beginning with value generation and then moving to IFRS earnings and capital. High-quality value creation continues to be supported by our diversified multi-market and multichannel platform. NBP generation came in at $1.4 billion, up 8%. Leaving out the Chinese Mainland, overall NBP growth would have been 10%. The 4% reduction in Chinese Mainland NBP reflected the combination of the margin impact from the increased share of participating business and the impact on sales volumes from the application of new industry-wide bancassurance expense rules. We're working closely with our bank partners to restore momentum and rebalance product mix, including expanding our preferred branch network with CITIC and launching a range of new products. We expect full year NBP to be similar to 2025 levels. By market, Malaysia stood out, with NBP up 46%; we also saw good growth in Hong Kong, with higher margins and a strong domestic segment performance. Thailand and India supported double-digit growth in our growth markets segment. From a channel perspective, the vast majority of our NBP generation is from proprietary distribution through our agency and bank partners. During the first half, agency expanded by 5%, while bancassurance kept up its strong performance, with NBP rising 13% in total, or 18% when excluding the Chinese Mainland. Our ongoing priority remains writing new business of high quality that generates capital. The group's NBP margin rose 2 percentage points versus a year earlier, reaching 40%; we achieved margin gains in both agency and bancassurance notwithstanding declines in the Chinese Mainland. Margin improvement came in Hong Kong and Malaysia thanks to a better mix of health and protection. Hong Kong additionally gained from further selective repricing measures. Health and protection products account for 33% of our NBP. The bulk of savings-related shareholder profits come from fee income inside participating and unit-linked structures, with only limited direct market risk. Above all, we stay focused on high-quality business that turns into cash, with appealing IRRs and brief shareholder payback periods. Embedded value operating profit rose 11% to $2.5 billion, powered by NBP growth, a stronger in-force return, and disciplined control of central costs. Measured per share, embedded value operating EPS climbed 16%, helped by lower noncontrolling interests in Malaysia and a reduced average share count stemming from our continuing buyback. On a headline basis and prior to accounting for capital distributions, the group's embedded value rose 6% across the 6-month period, reaching $40.1 billion. Per share, once capital distributions are allowed for and goodwill is excluded, this came to $15.27, a rise of 5%. Lastly, annualized, our RoEV stood at 15%. We remain of the view that sustained high-quality growth combined with disciplined capital management will underpin a 2 to 3 percentage point gain in RoEV over time. I'll now move to our financial performance seen through an IFRS lens. In our accounts, you'll notice we've made a modest adjustment to how we present our IFRS CSM and operating income, shifting to what we term a shareholder view, which removes certain policyholder items tied to reinsurance that can skew the individual lines within the source of earnings analysis. This produces a higher insurance service result alongside a matching decrease in the net investment result. Our guidance covering CSM structural growth, growth in the net investment result, and growth in operating EPS all remain as before. As is customary, I'll begin with how our CSM balance developed; it serves as a store of future profit, released gradually into the income statement as insurance services are delivered to customers. Our emphasis on high-quality new business lifted the CSM new business contribution to $1.4 billion, an increase of 9%. Combined with the normalized unwind and the release into the income statement, the underlying annualized CSM growth rate came to 7%. That is still within our 6% to 9% guidance range, though under what was reported in the prior period, reflecting lower start-of-period interest rates that mechanically lowered the rates of normalized unwind as well as a smaller relative contribution from new business. Economic and other variances totaled $0.3 billion. The income statement release came to $1.4 billion. That works out to an annualized release rate of 10%, which is somewhat lower than what we saw in the first half of 2025, and it reflects the growth we've had in longer-duration savings business in recent years. Taken together with adverse FX translation, all of this gave us a closing CSM balance of $26.8 billion. Moving to IFRS earnings, the $1.4 billion CSM release, which rose 10%, drove our insurance result. That represents roughly 3 quarters of insurance operating profit. The net investment result stood at $0.5 billion, an increase of 2%, consistent with the guidance we gave back in March. What we're seeing there is growth in life business surplus funds, held back by strong remittances to group as well as asset derisking activities in the Chinese Mainland. Experience variances, which sit in the other column of the chart on the left, came in at negative $27 million, versus a positive $24 million in the first half of 2025. That largely mirrors greater investment in capabilities along with start-up costs. All told, the overall insurance result is 5% higher. On the right-hand side of the slide, you can see a summary of our IFRS income statement. The headline asset management result is up 1%, as improved operating profit was offset by a lower share of earnings from our Indian asset management operations, or AMC, after the IPO in December last year.
If we look at things on a like-for-like basis, pre-tax earnings from underlying asset management rose 19%. Our disciplined stance on keeping central expenditure in check has been maintained. Corporate expenditure came in roughly level compared with a year earlier, while restructuring costs fell substantially. That favorable operating leverage helped push growth in group operating profit before tax up to 9%. The effective tax rate stood at 16%, and helped by a lower noncontrolling interest charge, shareholder operating profit after tax climbed 13%. Taking into account the 4% decline in the average share count, operating earnings per share rose 17%. Last, on capital generation: we are still making very strong headway toward our 2027 target of delivering in-force capital generation, or gross OFSG, above $4.4 billion. Gross OFSG rose 15% during the period, matching the guidance we gave in March. Behind that was continued growth in the expected transfer, which was up 16% to $1.6 billion, in line with the $3.1 billion anticipated for the full year. That gain mirrors the payoff from high-quality new business growth in recent years. Capability investment came to $145 million. I still expect it to land between $300 million and $350 million for the full year, which would largely wrap up our program. Positive variances in underlying operations are there, and I'll address those in a moment. In total, gross OFSG rose 15% to $1.8 billion. After that, we allocated $0.4 billion toward new business at appealing returns. Finally, factoring in the gain from reduced central and restructuring costs, capital generation at the group level climbed 41% to $1.2 billion. Our confidence remains firm regarding the 2027 gross OFSG target of more than $4.4 billion; growth in profitable new business will get us there, along with completing in-train actions that bring us back to long-term net positive variances. The chart on the left, which is now familiar, captures these main drivers. As 2025 wrapped up, the capital that will emerge in 2027 from life business already on the books stood at $3 billion. On top of that, during 2026 we're layering in profitable new business, which fuels capital generation in 2027 and afterward. In the first half, the contribution that new business made to 2027 capital generation came in 42% above the prior-year level. The main drivers there are the mechanical impact of moving into the structurally larger policy year 1 contribution compared with policy year 2, plus growth in underlying volume. As a reminder, the full-year 2025 new business addition was $0.5 billion, and for this year I expect like-for-like growth to be broadly in line with new business growth. Another essential element for hitting our 2027 gross OFSG target is returning to favorable operating variances and changes in assumptions. The fact that underlying variances came back positive—at $32 million for the first half—for the first time since 2020 represents a significant milestone. That outcome shows the continuing payoff from steps taken to strengthen underwriting profitability in health and protection, along with gains from better economies of scale as total costs rise at a slower pace than revenues. As I mentioned earlier, we expect to complete the bulk of capability investment program spending this year. Given that, I am confident we will generate favorable variances above $200 million in 2027. Money flowing up from the business units to the group center is holding up well. In the first six months, capital generated at the segment level—net of what we put into new business—reached $1.4 billion. The amount sent up matched that number. I'm still guiding you to a remittance ratio of roughly 70%, and I'd point out that the timing of these remittances tends to favor the first half of the year. At the holding company, that gave us $0.9 billion in free cash flow, which funded the 2025 second interim dividend and our buyback program, which continues. Other corporate activities largely reflect our bigger stake in Malaysia. Taken as a whole, our central liquidity position is still very strong, closing at a balance of $3.7 billion. The group's capital position continues to be robust. We gain from strong and improving capital generation, very strong regulatory capital ratios, and low financial leverage. Our GWS regulatory capital ratio came in at 268% on a shareholder basis and 195% on a total company basis; and our free surplus ratio was 209% at the close of the period, ahead of our 175% to 200% operating range. On a pro forma basis, once the full return of the AMC IPO proceeds is allowed for, this would be 200%. How the free surplus ratio moved during the first half reflects continuing organic capital generation, less capital returns to shareholders, and the increased stake in Malaysia. The progress visible in our first half financial performance and our strong capital position reflect our disciplined and active management approach to capital allocation and our focus on driving sustainable growth in value and capital generation; we keep executing consistently across our framework by maintaining a very strong regulatory capital position, and investing in new business with IRRs above 25% and payback periods under 4 years. Our capital management program is now firmly established. So far this year, we have returned $0.8 billion of capital through our buyback program. We're likewise actively overseeing our strategic portfolio to support durable long-term growth. I'll share a few more financial specifics regarding India, a key strategic market where we've shifted from a passive stance to a platform for controlled growth. There are two distinct yet connected transactions. The first is our agreement to purchase a 75% stake in Bharti Life. The second is the anticipated decrease of our existing 22% holding in ICICI Prudential Life, or IPru, down to roughly 10%. The initial cash consideration for Bharti Life comes to approximately $370 million, plus a possible extra payment of as much as $74 million, contingent on certain conditions being met. The transaction process is still underway, and multiple regulatory approvals are needed. Things are moving along on schedule, though finishing it will require a while, which is why our books don't reflect it yet. As for the second deal—the lowering of our IPru holding—part of the proceeds is earmarked to support upcoming growth at the Prudential/Bharti platform, while the rest boosts our free surplus. With an operating license now in hand, we'll continue directing capital toward building out our stand-alone health business too. That outlay will stay modest, given that we are testing, learning, and scaling alongside our partner, HCL. Results from the first half have shown once again how strong our franchise is and how powerful a platform that produces top-quality, compounding, sustainable growth can be; we hold leading positions across the highly appealing markets of Asia and Africa. Margins we're generating are attractive, and we're positioning the business to achieve double-digit performance for many years ahead. To sum up, our focus stays on driving high-quality growth and boosting returns for shareholders. We're moving quickly on our strategic priorities, maintaining bancassurance momentum while building up agency strength and quality. And we keep improving the quality of our new business so growth is sustainable and efficient. We stay strict about how we deploy capital: we put money into developing capabilities and into targeted bolt-on purchases that strengthen what the group can grow into later. We plan to increase the $1.2 billion repurchase we have slated for 2026 by roughly $0.3 billion, and the funding will come from the capital market steps we are carrying out now.
Our attention stays squarely on hitting the 2026 guidance we've set — double-digit growth in NBP, gross OFSG, operating EPS and DPS — and on meeting our 2027 financial objectives. And lastly, we're strongly placed in Asia and Africa, those long-term growth markets, and the opportunities in front of us still excite me.
A replay of today's call will be accessible starting Tuesday of next week. Anil will kick things off; and at this point I'll hand it over to Anil, our CEO, to get us started.
Our platform spans multiple markets and channels across both insurance and asset management, and its strength and resilience let us deliver growth that is consistent and high in quality. Our focus has been on speeding up how new business profit gets converted into cash, which in turn produces shareholder returns that are sustainable and growing. The progress of the last few years pleases me greatly, and so does our strong record of delivery as we transform and modernize potential; we repositioned the Hong Kong business by growing the domestic franchise substantially. That franchise now produces 50% of new business profit in this key segment, and we improved Chinese Mainland operations through a better product mix, risk management and strong capital levels, showed how broad our diversification is with ASEAN markets lifting new business profit by 13%, and our Indian and African business is growing APE at a double-digit rate. Next to our insurance operations, underlying profit in asset management rose by 20%. We are also focused on our strong proprietary channels, agency and bancassurance, driving productivity and widening our bancassurance footprint; a multiyear transformation of agency operations was launched, with productivity and quality recruitment as the key priorities. It pleases me very much that we have reported progress in these areas across both developed markets and emerging ASEAN businesses. We have built out health and protection operations that lead the market, helping customers navigate post-COVID medical inflation while delivering significant operating improvements, and driving innovation, AI adoption and a high-quality customer experience has been central to our $1 billion investment program in technology, in distribution, health and customers. Clear priorities for capital allocation have all been set, backed by a capital management framework that is comprehensive and sustainable. Good progress has been made in delivering more than $7 billion of returns to shareholders between 2024 and 2027; and to round off last year, we completed a highly successful IPO of asset management operations in India, creating substantial value for shareholders, and we are in the process of returning it. Most recently, as you may have seen, we are moving toward meeting the initial 15% free flow requirement. Proceeds of approximately $0.3 billion would be generated, and that will be added to our 2026 share buyback. Turning to first half results. We keep building on our record of delivery. Further investment was made in our high-performing business in Malaysia by increasing ownership, and we have fundamentally repositioned the India business by taking control of the 2 complementary insurance platforms of life and health. In the first half 2026, new business profit grew by 8%. Earnings per share grew by 17% and free surplus generation was up 15%. We also raised our first interim dividend per share by 15%. Our first half 2026 performance was well rounded, and we stay very disciplined on quality and on execution. I have 3 clear messages for our investors. To start, we are keeping a tight focus on hitting our 2026 guidance, on delivering double-digit growth throughout our key financial metrics, and on reaching our 2027 financial objectives. Next, our transformation agenda is moving along nicely as we keep building capabilities and modernizing both our operations and our technology platform. Third, we stay highly disciplined when it comes to allocating capital. We are putting money into quality growth, generating attractive margins, and achieving sustainable growth in capital generation. Given our multi-market, multi-channel model and our push for quality growth, I am excited about what lies ahead for us in the growing markets of Asia and Africa.
As Anil said, during the first half of 2026 we achieved double-digit increases in EPS, DPS and gross OFSG, along with 8% growth in new business profit. Our attention stays squarely on quality growth in new business carrying high IRRs and quick payback periods, and the compounding from that is what drives our strong capital generation and earnings. The new business margin widened by 2 percentage points to reach 40%, and by concentrating further on lifting agency performance and raising the share of health and protection within our newness mix, we have opportunities to keep enhancing margins over the medium term. Embedded value per share ex goodwill came to $15.27, or GBP 11.50, and our return on embedded value stands at 15%, with room to lift that by another 2 to 3 percentage points. Management of our in-force book keeps getting better — and we're glad that underlying variances have returned to positive territory; that's a significant milestone and shows the effect of our work on strengthening claims management, growing revenue premiums and containing costs. Thanks to these gains, we can keep investing in the business on a normal course basis while producing sustainable positive variances going forward. Strong persistency continues to benefit us, and in Hong Kong that figure is 99%; we will mostly finish our capability investment program during 2026, spending between $300 million and $350 million, and we're confident about getting back to positive variances above $200 million in 2027. In short, we're happy with how capital generation is trending — gross OFSG has risen 15% year-on-year and net OFSG has risen 41%; we'll keep building on that momentum as we work toward and past our 2027 objective year. The group's capital position stays very robust, and our gearing is conservative. Our free surplus ratio at 30th of June was 209%, or 200% once the remaining net proceeds from the AMC IPO are excluded, in line with the 175% to 200% range we set out; in January we launched a combined $1.2 billion buyback, due to finish by the end of 2026. And as Anil noted, with today's capital market actions, we had a further $ 0.3 billion of buyback to complete by year-end. We still expect to return another $1.3 billion in 2027, all of which contributes to more than $7 billion of capital being returned to shareholders between 2024 and 2027; to sum up, we delivered a substantial improvement in financial performance in the first half of 2026, with quality growth across our key financial KPIs. Looking ahead, our focus is firmly on delivering our 2026 guidance of double-digit growth in our KPIs and our 2027 financial objectives. Prudential holds leading positions in the highly attractive markets of Asia and Africa. We are producing attractive margins and positioning the business to deliver double-digit performance for many years ahead.
When you ask your question, kindly state your name and the organization you represent. Also, please submit your questions online. Especially if you're using a mobile phone—and for everyone else's benefit, so they can hear properly—please use the online service or dial in to the VoIP, which is much clearer. I'll now hand things over to Alex, our call operator, who will give instructions and open the lines for questions.
This is Kate. First, predictably, on new business value in Hong Kong—Anil, thanks for your double-digit growth guidance for 2026. A few things I'd like to unpick. Could you help us understand your base case for the second half a bit better? Should we assume domestic growth keeps running at the 20-plus level and MCB stays around where it was in the first half? And how much of that should we expect from margin versus volume—that's the first question. Second, just on new business strain. Sales were up 3%, and the 4% strain came in 11% lower. What were the main drivers? Are they sustainable? Or should we still keep the 11% to 12% of AP guidance in mind? And then lastly, very quickly on India. For the asset management business, do you intend to meet the free criteria and then stop there, keeping your stake stable? Or are you thinking something different? And should we expect all the proceeds to go toward reinvestment in the new entity? Or might some come back to shareholders?
Thanks, Kailesh. Lots of questions there. Let me begin with Hong Kong and the margin question, and then I'll hand over to Ben for new business strain as well as the AMC and <<inaudible>> question. First, let me zoom out a bit and give you some color on our Hong Kong business. I really like the shape of where it stands. As you'll recall, Kailesh, coming out of Corvid, we were heavily skewed toward the Chinese mainland visitor segment; today we're very much in balance. 50% is Chinese mainland and 50% is domestic. You're right that domestic did very well, growing 22%. That also underscores in many ways the focus we've placed on quality. We're very focused on driving our proprietary channels. And quality came through quite strongly with the 7 percentage points of margin improvement we saw. On top of that, we run a multichannel growth engine model. You'll have noted the strong bancassurance performance, and a combination of these factors is likely to continue into the second half of this year. On your specific question about CME, I'll try to keep it brief. We're not seeing any abatement in the drivers of demand. We're constantly in touch with our agents and our customers, and the structural demand drivers behind why Chinese mainland customers buy in Hong Kong seem very strong; so strong stake, margin improvement, strong bancassurance. We’re putting a lot of effort into making our agency perform better, and that’s why we feel positive about getting Hong Kong to double digits for the full year, including improving how we do in the second half. I’ll stop there and hand things over to Ben.
Alright. Thank you, Anil. Kailesh, taking those in the order you raised them, regarding new business strain, the benefit you're observing comes from a modest change in the product mix. The mix carries somewhat more power, which makes us more capital efficient. Country mix also introduces some nuances. What I'd point you toward going forward is to keep using 11%, 12% for APE when modeling strain. On your free float question, today's actions, I believe, show we are taking steps toward satisfying our free float requirements. As you'll remember, initially that requirement stood at a 15% free float, which later rises to a 25% free float. The proceeds, as you've seen, contribute to an already very healthy free surplus ratio. And naturally, capital we won't retain and don't need is therefore being returned to shareholders. Stepping back to the opportunity, India remains a very strategic market for the group, for asset management broadly, and as a wealth enabler. On your IPO sell-down question — well, first this depends on successfully completing our acquisition, and we are relevant parties regarding the sort of timetable for reducing shareholdings. As we stated in our presentation, we'll want to retain a portion of the proceeds from the initial acquisition, and also to fund investment in the Prudential Bati platform to accelerate growth. There will, however, be residual proceeds. We expect these to add once again to a very healthy free surplus, and hopefully that's likely to me.
One more point from me, Kailesh. We now have complementary channels across both life and health in India, and I'm pleased to share that we began writing our first policies in the health business earlier this month; and remember, this is the joint venture where we hold control, and we're delighted that we've been able to launch our health business in a market as strategic as India.
Okay. Thanks, Anil. Over to the next one. .
A few points. Ben, I believe you mentioned that the contribution from new business to gross operating free surplus generation in 2027 would track the business in line with the '26 contribution, while I think it rose 42% in the first half — could you clarify whether you expect the '26 contribution to be roughly 10%, or in line with growth in business profits? Second, within your 55,000 total, could you discuss MDRT in first half 2026 and how much they grew? And third, Ben, you mentioned the RV being 15% and hoped to improve by 2 to 3x. Where do you expect that to come from? Do you see it arising from stronger new business, from positive operating variances, or from shrinking the embedded value denominator?
Thanks for your questions, Andrew; so let's begin with the new business contribution to free surplus generation, and let Ben answer that. I'll take the MDRT question from Naveen, and then we'll sort of return to the ROE one.
Yes, thank you, Andrew. So that increase of 2 essentially reflects two factors. First, as you know, it involves moving forward by 1 policy year, and second, it comes from expansion of the book. Let me put that another way. When I consider what 2026 new business adds toward the 2027 target, a few points stand out. First, the cash generation profile we are writing aligns closely with the 2025 cohorts, and that, as you can observe in our accounts, would have contributed $0.5 billion toward 2027. So I would take that as a starting base and then simply build on it. But the growth we are adding to the book in 2026, if that makes — would you like to take it from here...
Is it new business profit or sales that grew?
Andrew, it’s profits — profits.
Let's go to the MDRT and then we'll come to the ROE question.
Andrew, thank you for that question. Let me respond in this way: first, as we've communicated in the US, our attention remains firmly on boosting the productivity of our agency force, and one element of that is expanding our MDRT franchise. We take real pride in holding the #2 MDRT franchise position. And we're looking to — as you can tell from the figures, NBP per active rose another 9% in H1 this year. That result stems from 5 initiatives, and we'll keep accelerating them through the second half of the year. Briefly, I'd say the first is that we'll keep shifting the quality of our recruitment toward quality schemes such as true ventures, which are already scaled up in the markets of Hong Kong, <<inaudible>> and which have been relaunched and refurbished in the markets of Indonesia and Philippines. Second, this year we launched, for the first time, a group-wide true MDRT program, which creates benefits, capability building and incentives for MDRTs across every market; and as you'll recall, we also made compensation changes early in the year favoring high productivity agents, and we expect some benefits from that to come through particularly in the second half of the year. Third, we've had good success launching affluent propositions. Our case sizes went up by 6% in H1 this year — you'd have noticed that figure — and we're poised for additional affluent proposition launches in our key markets during the second half. So that will be one more, Philip. Fourth, Ben already noted that we pivoted quite strongly toward health and protection, which has driven our margins. And we have further initiatives to enhance health and protection within our agency channel. And last but not least, there's significant investment in AI and technology on the agency platform to drive productivity. Our True Action 1.0, which is our AI module for performance management, is now live in Singapore across 5,000 agents. I'm pleased to share that users have improved productivity by more than 13%. Now, on your specific question about what the actual growth in MDRT numbers is: what I can share is the following — MDRT is a full year phenomena; we are at the half year stage. And we will continue to focus on that as we go forward. What I can share specifically is the contribution of MDRT and the strong line that we have on MDRT. So I'm now referring in particular to agents who have already crossed 70% of the MDRT threshold — the contribution of APE from this cohort, and from people who've already become MDRTs, remains exactly what it was last year. So we are pretty much dead on where we were last year; and we will look to accelerate in the...
Now, returning to what you asked about ROE, Andrew. The foundation there is double-digit expansion in new business — we're a business growing at a double-digit rate. I'd say the 2 to 3 points really come from two places: first, finishing the investment and capability program that you know about, and second, improving variances. And I'm happy with how far we've come on that front. As you'll have noticed, we're back to net positive underlying variances and positive underlying claims experience. What will begin to pay off now is scale coming through in the end, along with greater operating leverage; and in the appendix of my presentation there's a slide that shows our operating leverage ratio improving by 40 bps during the period — so that's where the uptick will show up.
Okay. Thank you. Back to Alex for the next question, please.
Three from me. First, can I ask about the double-digit growth for the group in NBP, given China is broadly flat? I understand Hong Kong will be double digit, but what's lifting the rest? Second, on Malaysia, I noticed MDRT 2026 was up 4%. Business profit looks pretty good too. Where can you actually draw — can you draw any lessons from this Malaysia business and apply them to other places and geographies as well? And finally, on the short-term leases below the line, the $66 million, where does that come from — is there actually economic versus noneconomic in there? China is typically an economic move.
Thanks, Nasib. The first one I'll direct to Naveen, the second to Ben, and then I'll address the third — your third question. So we are firmly focused on delivering our guidance of double-digit growth across a range of financial metrics, and pretty much aligning that with our objectives for 2027 as well. You're right to point out that we believe we'll carry some of the positive developments in Hong Kong into the second half. We also believe growth will resume in China; we're taking a number of steps to firstly conform to the new expense regulations, as well as having a slew of actions in force to get our product mix in balance. So that should hopefully bring positive growth in the second half in China; but at the end of the day, we have a multi-growth — or rather multi-market — growth model. So if you look at our Malaysia business, it did very well. Talen had an outstanding first half, and we believe we can take the growth in Singapore from mid-single digit to high single digit, if not early double digit. And we're also starting to see a turnaround come through in our Vietnam business; so remember the Vietnamese business has been negative — growth for us, and it's starting to get marginally positive. And we're hopeful that it will start to grow as we go through the second half of this year. So we have a number of markets that will complement some of the growth we're going to see in Hong Kong, which gives us the belief that we'll be able to get to our guidance for 2026. I'm going to go to Malaysia, which had a very strong performance. Naveen, do you want to tee that up?
Sure, and thanks to you, Anil, and Nasib, for raising the Malaysia question. As the figures show, Malaysia posted very strong growth during the first half, driven by an outstanding showing from Agency and killer, and if you remember, agency had been shut previously and turned things around in last year's second half. Malaysia is the number one emerging ASEAN market where our agency transformation has gone furthest in implementation, and on your specific point, I believe there are three major learnings from Malaysia that will keep its performance going over the coming few quarters and across ASEAN markets. The first is an emphasis on quality recruitment. We discussed this last time too, namely the drop in Malaysia, and we are now seeing that the incoming group of recruits actually drives productivity at 5 to 6x what normal organic recruits deliver, and the focus increasingly is on ensuring a growing share comes from the pro venture recruit. The second is a tailored proposition for the agency, mainly around health and protection, but also a set of propositions addressing HNI and affluent needs in Malaysian markets, which worked really well for us in the first half. Those are learnings we will also carry into other markets, especially Indonesia and the Philippines, where we launched Pro ventures or refurbished it during the first part of this year, and we plan to launch some of these protection and affluent propositions in the second half. And third, I am very pleased to share that Malaysia saw very strong growth in active agents in the first half, supported by some of the agency management initiatives we have put in place, and again those give us learnings for some emerging ACM markets as we move forward, so overall, strong performance from Malaysia and sustainable growth as we see it ahead, particularly driven by agency, with plenty of learnings we are already taking to other emerging ASEAN markets.
Nasib, just one more thing from my side. So even though we're still optimistic about Malaysia's growth outlook for the second half, given all the factors Naveen brought up, do you anticipate the <<inaudible>>.
You had the rate cuts in China, which brought down the discount rate we use for the GMM contract and also reduced spreads. Then, second, rates went up more widely in a lot of our markets, so there was a mark-to-market effect on the bond holdings that back shareholder business. On top of that, you get the discounting effects that push us toward a lower present value of future profits in health and protection business. So you could argue that many of those movements are tied to the discount rate rather than to underlying economics. What I'd highlight — and I'm certain you've spotted it — is that we actually had positive unlocking in the CSM, and that goes part of the way toward offsetting the minus 0.6%. The unlock contributed 0.4 positive, and that reflects long-term equity returns coming in better than expected across a number of our markets.
Alex, we go to the next one.
Alright, a few points from my side. I'll begin with Mainland China. We got off to a very strong start this year, and then obviously regulatory impacts came into play in 2Q and in all likelihood will carry into a portion of the back half as well. I really do value the added transparency around quarterly trends for the Mainland China business. That said, could you help me understand seasonality — what would a normal seasonal shape for Mainland China look like? Typically, 1Q comes in very strong while 4Q is quite weak. So I'm simply unsure how to interpret the figures in terms of how elevated the price is relative to how low on a basis? In conversations with peers in insurance, the usual breakdown tends to be around 30% or 35% for 2025, then 25, with the last quarter at approximately 15% — fairly similar for the protein business in China. Next, turning to Singapore: APE there has been quite robust, yet the markets have been somewhat behind. So I'd like to understand when the markets might start to recover and when agency results will begin to show somewhat more improvement, since at present bancassurance seems to be the one that's dropping? And finally, Bancassurance — sorry, OFSG, OFSG — the inflection point, looking at it as of the first half and probably for the full year, we're looking at mid-high teens, most likely, which means that to hit the 2027 target, next year's OFSG growth will clearly be at the high end of that inflection point — so how should we then be thinking about modeling going forward after 2027?
Michael, let me begin with your first two questions, and then I'll turn to Ben for the surplus generation one. So in China, as you're aware, for the past 3.5 years we've been highly focused on driving transformation. That was very evident in how 2025 turned out for us, and we brought that momentum with real force into 2026. You're correct that the first quarter is usually the entry point and generally the largest one of the year; in quarter 2 we felt the effect of a power mix that came in above what we had expected, along with regulatory shifts. Turning to the back half, three priorities guide us: first, quarter 3 brings a substantial competitive presence in China. For us, July, August and specifically were exceptionally strong months in 2025. So that's a challenge we'll have to manage. From September onward, competitors will start easing conditions significantly, so to address what you asked, the way we expand in China—or how we produce new business profit there—will likely appear somewhat different than what you probably observed in 2025. On your second question about Singapore, we achieved volume growth in both agency and bancassurance. The difficulty we ran into came from the fresh copayment regulations; that is the area where we needed to adapt to the revised health guidelines the government rolled out, which as a result weighed on margins, as you correctly noted. Naturally, in Singapore we provide the complete product lineup, and we've rolled out newer protection offerings that extend our health continuum, plus inventive options designed for the requirements of high net worth and ultra high net worth clients. This makes us confident that we can counter a portion of the nearer-term difficulties tied to health or the changes to health regulations as we progress through this year's second half. Bear in mind that in Singapore we hold a household brand, extremely strong in agency and also via our partnerships with Standard Chartered and UOB in Singapore. With that, I'll pause and hand it to Ben for the free surplus question.
Absolutely, Anil. Michael — thanks. So listen, we feel really good about where we stand when it comes to generating capital, and we have strong confidence in hitting our 2027 OFSG goal of $4.4 billion. There's a slide in the appendix of my presentation that lays out how the free surplus ratio has developed. When you're modeling our OFSG past 2027, I think it helps to think in terms of those building blocks. In short, the in-force generation — that expected transfer — keeps growing at a strong pace. As you know from what we've said previously, we've set dividends and the added recurring capital returns at levels that can be sustained, and once you allow for those, we expect to sit at the end of our free surplus range. So when you model that, factor in the acceleration you mentioned toward our objective of $4.4 million. As I've noted before, I'd still point you toward required capital rising at an early double-digit pace. Earlier on this call I gave you the rough yardstick to use for new business strain. Central costs should stay pretty much flat, and that, I think, hands you all the ingredients — nonoperating is a bit tougher to guide on. That, as you know, reflects things like market movement effects on the regulatory balance sheet, some of which aren't really economic in nature. And the slides show that, on a pre-capital returns basis, if you annualize it, we're producing mid-double-digit growth in the free surplus ratio. So hopefully that gives you a sense of it.
Alex, let's take the next question, please.
Michel here from Citi Research. Well then, to begin, congratulations on these results, especially given such a tough environment and a very high base. I have 2 questions. The first one is on — I think 6 isn't a typical year, what with so many regulatory disruptions and the shifts in product mix; I just wonder, since pulp products already represent over — represent almost 80% in the first half and that led to some margin deterioration, can we see — can we say the product mix change is kind of done? And right now, we're fairly satisfied with the product mix. And next year, there won't be like — there won't be that kind of drastic margin deterioration. And next year, there won't be any kind of high base or no disruption, so that for the China business, we're confident of going back to the high-growth trajectory. That's the first question on margin deterioration and the sustainable growth level for TPL. The second question is on — it's quite interesting, and we appreciate your sharing the result of our survey that within the next 12 months, is it still like 74% of CME? They have planned to be in Hong Kong, and 88% of them are going to purchase insurance products. I just wonder whether there's anything more you can disclose about this survey, because we're seeing the H&P product growing faster. Have they disclosed which type of products they'd be more interested in, given the current concern over taxation of insurance products? Just want to get a sense of how our Hong Kong MCV product mix is going to change, given the fantastic update you've done.
Michel, thanks for that question. So let me begin with the second one, because as you can imagine, we're in constant touch with our customers and our agent partners, and we've kind of shared some of the slides regarding the feedback we're receiving. And I'm glad to share that we've just received the feedback from the most recent survey we conducted in August; and the feedback is very much similar to what we've already kind of shared on our slides, which kind of gives us confidence that the demand drivers behind why Chinese visitors buy policies in Hong Kong pretty much remain intact. And as I said, we'll continue to kind of stay close, because there's a lot of news, as you can imagine, right now — and we're in constant touch with both our agents as well as our customers. So I'll stop there, and I'll move to your CPL question on the first half, what we're doing in the second half and specifically the guidance on margin. Angel.
Absolutely. Thanks, Anil, and thanks for the question, Michelle. I believe we correctly highlighted that this year you're witnessing two developments in CPL. The first is the toregulatory change involving banker expense alignment, and the second is the significant product mix shift toward par. As you're aware, CPL has effectively shifted its product mix to par, rising from a low single digit to 40% last year, and in the first half it stands at 76. That explains some of the margin compression you're observing; nevertheless, we moved quickly toward our protection business in quarter 2, particularly in Jens, where we're seeing quarter-on-quarter margin uplift parity. In the second half, we'll concentrate on the protection product and on optimizing margin for the power savings product — in August, in fact, many of the non-power products have been onboarded at most of our partner banks; so you should expect that for the full year, we aim to bring our power mix to roughly 60%.
And Michel, as far as what to expect on the margin side goes, at the moment we're aiming for a roughly 40% margin in China for the full year, compared with 43% for the whole of 2025.
Okay. Thank you. Next question, please, Alex.
I have three questions, if that's alright. For the first—well, actually, following up on all your comments regarding new business—you gave us a good level of detail on the building blocks, which I found pretty useful. So thanks for that. But let me step back to the big picture. You applied the term "firmly" to new business profit and to double-digit growth for '26. In 1Q, I believe you said—sorry—definitely committed, and you want to use the term "confident." I'd just like to hear it from you: has anything changed here? Do you see a very high probability that you'll deliver this? Or are you essentially telling us, guys, <<inaudible>> long-term vision for India. You're swapping out a really large life partnership—though one with a small stake that's been losing ground in India—for a considerably larger partnership where you'd have control plus a health venture. At what point, in your view, does that become greater than or equal to what you already hold, assuming a world where regulatory approval comes through and so on? And my final question, very quickly, is for Ben: I know there were some shifts in the IFRS profit, the CSM and the investment margin. Could you give any guidance on those items? You already mentioned CSM growth, but on the investment margin specifically, anything else?
Thanks, Farooq. Let me begin with the guidance question. I'll direct the India and IFRS one to Naveen, and Ben gets the other. In short, our 2026 guidance stays as it is. As I've mentioned, we're squarely concentrated on delivering our second-half targets so we can hit that guidance, and equally concentrated on our 2027 financial objectives. There are a couple of factors we need to work through. The first is the elevated competitor base in both Hong Kong and China during July and August, which begins to lessen considerably starting in September. We've also provided plenty of detail regarding Hong Kong and the steps we're taking in China to bring that market's trajectory back to where it should be. Second, there's clearly a transition we need to work through concerning the expense guidelines in bancassurance. To reiterate, Angel offered some detail regarding what to anticipate on two fronts: the upcoming business launches, and how those launches would support a shift back toward a far more balanced product mix, along with the resulting effect on margin improvement compared with what we saw during the first half of this year. Those are the matters we are working through. That said, we are not at any point altering our guidance for 2026 or our confidence in the 2027 financial objectives. I'll end my remarks there. For the India question, I’ll turn it over to Naveen, and after that, Ben, could you handle the IFRS 1 item?
Thanks, Anil. As Anil mentioned before, Farooq, India is a strategic pivot for us in terms of how we pursue that market; and if we get regulatory approval for our life insurance transaction, we will occupy a genuinely unique position there as the multinational insurer covering both the stand-alone health vertical and the life insurance vertical. We also hold the distinctive position of partnering with two exceptional corporate groups — CL on the health insurance side and Bharti on the life insurance side. We think those two platforms, along with these strong corporate partners, will give us a big chance to address a very large protection gap that remains unmet on both the mortality and morbidity sides—so that's the long-term thesis. What we're really focusing on over the next three to five years is developing high-quality, profitable business. That is truly our goal. The components of that: we believe there are meaningful customer segments whose needs aren't being met. And interestingly, they range from the missing middle in health all the way to high net worth on the life side, plus the cross-border opportunity in health as well. So when it comes to the opportunities we pursue from these two platforms, we'll be very selective yet very sharp. Next, there’s still a major opening: expanding our agency force in a high-quality way, drawing lessons from our experience in certain other markets and concentrating on health and protection. In India—particularly in life insurance at present—the market is still overwhelmingly oriented toward savings and ILP products, and we intend to offer a distinctive approach there. Third, Bharti — especially Bharti Life — already has a number of bancassurance arrangements with several banks in the country, and we'll aim to expand that further, while also building on our partnership with Standard Chartered across both the life and health franchises. And finally, I believe that within both HCL and Bharti, we see some quite compelling opportunities in their ecosystems across these two corporate groups. For instance, Bharti serves 450 million customers, of whom 50 million are postpaid, high-value customers. India is a deeply digital market. We intend to pursue innovation and put money into direct-to-consumer and digital AI, testing whether we can seize this opportunity and turn a meaningful share of those customers toward our protection offerings across both life and health. And my final observation regarding India is that it's an enormous geography. Our focus over the coming five years — addressing your question — will be on roughly 100 to 120 cities. Our geography strategy is highly disciplined when it comes to reaching revenue pools, while also weighing it against the claims experience and profitability we observe and how we plan a considered expansion of these channels. To put it simply, over the coming 5 to 10 years, I believe you should anticipate that India will become a significant franchise for us across several measures. That said, during the next 5 years, our focus is simply on building out the pieces of the business I described. Thank you.
Yes. Farooq, thank you for that question. I think the best thing is to turn to Slide 34 in my pack and work through that table. Clearly, we were quite happy with the 17% increase in OPAT per share, and that translated into underlying OPAT growth of $13 million. The reduction in noncontrolling interest was, of course, tied to Malaysia, and that provided a growth rate benefit — all of which brought us to 9 points of operating profit before tax growth, roughly speaking. Within that, and as I've indicated previously, we will keep — continue to keep central costs firmly under control. My guidance on restructuring costs for the full year, coming in at just under $100 million, still stands. Moving up to the total segment result, the key component of which — or the largest component of which is, of course, insurance, we were very pleased with the strong growth in the release from the CSM — that was somewhat held back by a lower net investment result, which I had guided to earlier. And that came from 2 things: first, asset derisking in China, and second, lower surplus in our life businesses owing to higher remittances. That effect will begin to normalize somewhat on the growth rate as we move through this year, and I would expect a net investment result that is a couple of points higher. Finally, there is the progress we are making on variances. And as we accelerate into 2027, the benefits from that, together with lower investment in capabilities, will flow through into the earnings results; so I think, stepping back, given the strong structural growth in the CSM since IFRS 17 began up to now. And at this point I think our CSM is roughly 30% higher than it was then; and with what I just mentioned about improving underlying variances, I am very confident in the double-digit EPS growth outlook for the group on an IFRS basis.
Alex, I’d like to respect everyone’s time since we’re going to wrap up soon; there are 3 additional questions we’ll take. Could we make the questions fairly quick and we’ll answer them quickly too. Please go to the next one, Alex.
Thank you, Patrick, for that introduction—and for not prejudicing me. So, first question, please—I'm still trying to get my head around the outlook for new business growth. Sorry about that. But could you pause once more on the growth markets? In the second half, should they be accelerating relative to what you achieved in the first half, thanks to the good things like Thailand and Vietnam that you mentioned? Or does a risk remain that they decelerate, since there are other big moving parts such as Taiwan. Sorry—it's quite a significant division, and I'm still not entirely clear on the different moving parts within it; and I would have thought that over the longer term, the growth markets should be blowing past your double-digit target, rather than merely matching it. So I'm just trying to get comfortable on that, both short term and long term, please. And then secondly—I'll keep it to 2 questions. Again, you've already spoken convincingly about productivity and the MDRT in the agency channel. I'm still a little disappointed that the total number of active agents declined to 55,000. And I thought that with Malaysia stabilizing, we'd be back into growth in that number; so I appreciate the improvement in quality. I'm still slightly uncertain about the quantity. So from your point of view, do you simply not care, because that's a very bad metric so long as the other metrics are working? Or at some point, should active agents return to growth—and if so, could you give me a thought process about the timeline for that, please?
Thanks, William; so on your question about growth markets, we believe we have a range of markets in that segment that will continue to perform quite well as we look to the second half. So you could expect double-digit to probably mid-teens growth in new business profit growth for these markets, because, as you rightly pointed out, there are significant markets like Taiwan, and Thailand has done exceptionally well for us. Africa continues to grow very well. So you could expect, as I said, double-digit to mid-teens growth as we go through the second half. On the whole agency piece, before I hand it over to Naveen, the focus on quality has been quite deliberate, and we are pressing 2 levers, William. One is, as we've said, quality recruitment, driving active agents. And we've launched a number of initiatives in that regard to be able to press forward not only in debook, but also in emerging ASEAN markets, and the second is productivity. And you've seen year after year that we have shown measurable improvements on productivity. First, since we’re seeing — on the — from a demand perspective, there’s demand coming in for high-quality advice — but on the second front, we’re also moving our propositions uptier to emerging affluent as well as affluent customers. I’ll pause there. I’ll ask Naveen to give you a bit more detail on productivity versus active agents.
Thanks, Anil. Following Patrick's instruction, I'll keep this quick and to the point. I think, just getting to your particular question about actives, I want to break the issue into parts. First, in the developed markets, as you've observed, between '23 and '25, we increased our actives at a rate of 15% per annum — actually above 15% per annum. In H1 this year, in developed markets — Hong Kong, Singapore — actives are flat, owing to strong competitors and specific circumstances that we've discussed. So our historical difficulty with declining actives has really been in emerging ASEAN. I just wanted to split the problem apart and concentrate on emerging as here. Inside emerging ASEAN, if you look at our 3 largest markets — Malaysia, Indonesia, Philippines — Malaysia, as I said, has increased actives at 10%. Malaysia Life has increased actives at 10% in H1 this year. And turning to Indonesia and Philippines, where our agency transformation is still very much in flight — we will seek to improve actives. There's no question about that. It isn't a metric we don't care about, to be super clear on that; but what we also care about is the quality of those actives. And let me bring you back to the point we made on the Pro venture recruits, right? If they deliver 6x the productivity of normal recruits, then every 1 of those actives is 6x a normal active, right? And we are in fact pivoting away from that model of mass recruitment, part-time agency in Indonesia, Philippines and Malaysia, toward quality recruitment, full-time agency. And so our actives will grow. But more importantly, the quality of those actives will grow as well as we move forward. Thank you.
Great Okay. Let's go to the next one, Alex.
I'll keep this brief. First, on tax enforcement and the noise surrounding it: could you tell us what share of in-force business earnings or EV derives from the MCV, savings, or other investment operations — the restaurant business — that could be affected by that enforcement, and have you noticed any shift in lapse behavior over recent weeks? That's my first point. My second point follows the earlier question about the agency. The total 55,000 number is declining more slowly, clearly. But are you aiming at a specific target, the 550? It appears you're shifting direction, which might imply we should expect additional declines. I just want to understand that piece. And very, very briefly, a final question on Eastspring. There appears to be roughly a 2 bps revenue margin decrease and the cost-income ratio has risen. I'm just curious where that ends up.
Abid, let me take the agency question first. I'll address the tax enforcement and in-force point, Ben, and then Rajeev can cover your cost-to-income ratio question. On agency, as we've stated repeatedly, we're working both levers: productivity and quality recruitment feeding into active agents. We want to see active agents begin to grow — there's no doubt about that. Naveen outlined some measures we're implementing, particularly in the emerging ASEAN markets, shifting from a mass recruitment approach to a higher-quality one. The reason, as I mentioned, is twofold. First, customers expect high-quality advice. Second, we're pushing our propositions toward more affluent and high net worth customers. So yes, we'd like the active agent base to grow, but gradually and aligned with productivity gains over time. I'll turn to Ben on in-force. Then Rajeev, please pick up the cost-to-income ratio on ASI.
Yes. Abid, thank you for that question. So, when it comes to our Hong Kong operations, roughly 50% of the VIF is tied to visitors from China Mainland. Within that portion, 55% is made up of health and protection products — and actually, just to give you a sense, of the remaining share that's savings, our savings products naturally carry protection features built in, so they aren't purely savings or wealth products. We've seen no impact on lapses, and persistency, retention ratios are phenomenally strong. Also, the bulk of the payments — 95% plus for these products — comes from funds already made here in Hong Kong. So it's high-quality, sticky business; people aren't purchasing these products for some sort of tax reason.
Rajeev, do you want to pick up the...
Yes. Thank you, Anil. Yes, definitely. Look, we delivered a really strong set of results in the first half, as you can see in the deck — strong inflows and very strong investment performance across our capabilities. The decline in the cost income ratio is largely because of the IP AMC sell-down mechanics, and that is really what has pushed the cost income ratio up. But overall, our business mix has been very positive. Fee income ratios remain strong, and we are very pleased with the first half results.
Thank you, Rajeev. And last one, Alex, and then we will draw a close.
Let me ask the last few questions. Maybe first, if I return to Mainland just to clarify, in the announcement, you said full year '26 will be similar to full year '25; so that's on the CR basis, correct, so which would roughly imply the second half will be somewhere around 10% growth. Is that the right way to interpret that? .
The short answer is — so you had 1 more question. Go ahead. Go ahead, please. .
Yeah, sorry. And my second question relates to the Hong Kong margin. It's really, really encouraging to see that margin expansion in the first half. I just wanted to ask whether you could shed a bit of light on what is behind those savings — because I'm not sure — is it product mix, or which kind of product, or was it premium term? A little more detail there would be great.
Thanks, Thomas. So regarding the China question, I suppose the short answer is that it's on a CER basis. When we talk about the guidance for the full year, that's a range similar to what we saw in full year 2025. So you're correct on that. On HK margins, I'll hand over to Ben, who can give you some further detail on what's driving that.
Thomas, there are really two factors at play when it comes to margin. The first is better mix; we've performed strongly in the H&P area in Hong Kong, with both visitors from Mainland China and, in fact, the domestic segment. So that has provided a lift to our margins. Measured on a policies count basis, in fact, H&P accounts for 57%, 58% of what we offer; so that pleases us. There was additionally a slight mix shift involving certain of our savings and protection products stemming from repricing, which delivered a further boost in that regard. So the improvement in margin pleases us.
All right. Thanks, Ben and Anil. I'll hand things back to Anil so he can wrap up the call quickly. Thanks for tuning in. He has a few closing remarks for you.
Thanks, Patrick, and thank you all for those questions. We'll be out on the road very soon, so we'll have a chance to carry this conversation further in person as well. But I do want to acknowledge the enormous commitment and the hard work of those who have been driving the transformation for nearly 4 years now, and you're beginning to see some of that effort paying off in our results. I'd also like to take this opportunity to welcome Sir Douglas Flint, our new Chair, who has just chaired his first board meeting. I, together with the management team, look forward to working with Douglas and the rest of the board as we keep delivering on our financial objectives. Thank you very much, and we'll stay in touch as we head out on the road. And hopefully, we'll get a chance to see you in person. Thank you.
Thank you. Alex, you can close the call now.
Thank you, everyone, for attending. You may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Prudential plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Prudential plc earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.